<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002078</url>
  </required_header>
  <id_info>
    <org_study_id>082A</org_study_id>
    <nct_id>NCT00002078</nct_id>
  </id_info>
  <brief_title>Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection</brief_title>
  <official_title>Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue Frederick</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henry M. Jackson Foundation for the Advancement of Military Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the safety and tolerance of subcutaneous injections of natural interferon alpha
      (IFN) in asymptomatic HIV-positive persons and record its effects on the HIV virus in these
      individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon alfa-n3</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  HIV-1 seropositivity.

          -  CD4 count &gt; 400/mm3.

          -  Eligibility for care in the military medical system.

        Prior Medication:

        Allowed:

          -  Acyclovir.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  AIDS- or ARC-defining condition (unexplained weight loss, fever, diarrhea, night
             sweats).

          -  Evidence of AIDS dementia.

          -  Chronic hepatitis with severe liver dysfunction.

          -  Active gastrointestinal, renal, respiratory, endocrine, hematologic, cardiovascular,
             or psychiatric disorder that would limit ability to complete the study.

          -  Hemophilia.

          -  Co-existent disease likely to result in death within the next 2 years.

          -  Known hypersensitivity to human interferon alpha.

          -  Known anaphylactic hypersensitivity to mouse immunoglobulin (IgG), egg protein, or
             neomycin.

        Concurrent Medication:

        Excluded:

          -  Any other concurrent experimental medications.

        Patients with the following prior conditions are excluded:

          -  History of AIDS- or ARC-defining condition (unexplained weight loss, fever, diarrhea,
             night sweats).

          -  Evidence of chronic hepatitis with severe liver dysfunction.

        Prior Medication:

        Excluded within 5 days prior to study entry:

          -  Immunosuppressive agents.

          -  Chemotherapy.

          -  Steroids.

        Excluded within 45 days prior to study entry:

          -  BCG vaccine.

          -  Isoprinosine.

          -  Other immune modulators.

        Excluded within 3 months prior to study entry:

          -  Any form of interferon.

          -  Antiviral therapy.

          -  Immunoregulatory therapy (other than acyclovir).

             1. Active drug abuse (narcotic or alcohol abuse documented within the past 6 months).

          -  Unlikely or unable to comply with the requirements of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Walter Reed Army Institute of Research</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natl Naval Med Ctr</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Skillman DR, Wagner K, Malone JL, Decker C, Paparello S, Meltzer MS. Phase 1 study of interferon alfa-N3 in asymptomatic HIV-infected persons. Int Conf AIDS. 1993 Jun 6-11;9(1):468 (abstract no PO-B26-1998)</citation>
  </reference>
  <verification_date>November 1993</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Evaluation</keyword>
  <keyword>Interferon-alpha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

